CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill combo aims to shrink tough prostate tumors
Disease control CompletedThis early-stage study tests two oral drugs (darolutamide and abemaciclib) plus standard hormone therapy in men with high-risk prostate cancer that has spread or may come back. The first part finds the safest dose; the second checks if the combination can shrink or eliminate tumo…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Praful Ravi, MB BCHir, MRCP • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Old chemo drug shows promise for genetic subtype of prostate cancer
Disease control CompletedThis phase 2 trial tested the chemotherapy drug carboplatin in 16 men with metastatic castration-resistant prostate cancer that has specific gene changes in the homologous recombination pathway. The goal was to see if carboplatin could shrink tumors or lower PSA levels. The study…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New pill shows promise against tough prostate cancer
Disease control CompletedThis study tested a drug called ARN-509 in 127 men with advanced prostate cancer that had stopped responding to standard hormone therapy. The goal was to find a safe dose and see if the drug could lower PSA levels, a marker of cancer activity. The drug works by blocking male horm…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Aragon Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Old drug, new hope: niclosamide combo tackles tough prostate cancer
Disease control CompletedThis early-stage trial tested the safety and best dose of adding niclosamide (a drug used for tapeworm infections) to standard hormone therapy (enzalutamide) in 6 men with advanced prostate cancer that no longer responds to hormone treatment. The goal was to see if the combinatio…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo shows promise for Hard-to-Treat prostate cancer
Disease control CompletedThis study looked at a combination of two drugs, talazoparib and temozolomide, in 16 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The goal was to find the safest dose and see if the drugs could shrink tumors. The study was completed…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Can hormone swings tame resistant prostate cancer? small study tests a bold idea
Disease control CompletedThis early-phase study tested a new treatment schedule for men with castration-resistant prostate cancer. The approach alternates between giving testosterone through the skin and the drug enzalutamide, aiming to control the disease. The main goals were to see if this schedule is …
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Radioactive therapy shows promise for tough prostate cancer
Disease control CompletedThis phase 2 trial tested whether adding a radioactive drug (I-131-1095) to standard enzalutamide therapy helps men with a specific type of advanced prostate cancer that had worsened on another treatment. The study enrolled 120 men with PSMA-positive metastatic castration-resista…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Progenics Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Could a hormone Flip-Flop tame tough prostate cancer?
Disease control CompletedThis study tested a two-step treatment in 15 men with metastatic castration-resistant prostate cancer. First, they took high-dose oral testosterone for three 28-day cycles. If the cancer grew, they switched to enzalutamide. The goal was to see if oral testosterone could control t…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Steroid shot may buy time for men with tough prostate cancer
Disease control CompletedThis trial tested a steroid injection called triamcinolone in 55 men with castration resistant prostate cancer, a type that no longer responds to standard hormone therapy. The goal was to see if it could extend the time before chemotherapy is needed, since current steroid treatme…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Barts & The London NHS Trust • Aim: Disease control
Last updated Jun 26, 2026 14:49 UTC
-
Blood test may predict prostate cancer drug response, avoiding painful biopsies
Knowledge-focused CompletedThis study looked at whether a blood test could predict how prostate cancer responds to the drug abiraterone. Instead of taking a tissue sample (biopsy), researchers measured tumor cells circulating in the blood of 40 men with advanced prostate cancer. The goal was to see if chan…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC